Lumos Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2009
Net Income	-37.13	-34.03	-31.06	-30.43	-6.31	-12.75	Upgrade
Depreciation & Amortization	0.04	0.04	0.05	0.22	0.58	0.04	Upgrade
Share-Based Compensation	2.32	2.32	2.32	2.88	1.07	0.18	Upgrade
Other Operating Activities	-0.02	0.57	2.07	-2.31	-18.99	0.4	Upgrade
Operating Cash Flow	-34.79	-31.1	-26.62	-29.65	-23	-9.09	Upgrade
Capital Expenditures	0	0	-0.02	-0.03	32.47	-0	Upgrade
Acquisitions	0	0	0	0	84.18	0	Upgrade
Change in Investments	14.21	10.74	-11.34	0	0	0	Upgrade
Other Investing Activities	-	-	-	26	-	-	Upgrade
Investing Cash Flow	14.21	10.74	-11.36	25.97	116.65	-0	Upgrade
Share Issuance / Repurchase	-0.25	-0.55	-0.59	-0.08	0.1	0.02	Upgrade
Debt Issued / Paid	0	0	0	0	-0.03	0	Upgrade
Other Financing Activities	-0.03	-0.03	-0.24	-0.11	-	-	Upgrade
Financing Cash Flow	-0.27	-0.58	-0.82	-0.19	0.08	0.02	Upgrade
Net Cash Flow	-20.86	-20.93	-38.8	-3.87	93.73	-9.07	Upgrade
Free Cash Flow	-34.79	-31.1	-26.64	-29.68	9.47	-9.09	Upgrade
Free Cash Flow Margin	-2281.44%	-1516.09%	-1749.44%	-12903.48%	5638.69%	-	Upgrade
Free Cash Flow Per Share	-4.29	-3.82	-3.18	-3.56	1.40	-6.98	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).